Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Gideon M. Blumenthal; Paul A. Bunn; Jamie E. Chaft; Caroline E. McCoach; Edith A. Perez; Giorgio V. Scagliotti; David P. Carbone; Hugo J. W. L. Aerts; Dara L. Aisner; Jonas Bergh; Donald A. Berry; Anthony Jarkowski; Nicholas Botwood; Darren A. E. Cross; Max Diehn; Nicole L. Drezner; Robert C. Doebele; Collin M. Blakely; Wilfried E. E. Eberhardt; Enriqueta Felip; Luca Gianni; Steven P. Keller; Patrick J. Leavey; Shakun Malik; Francesco Pignatti; Tatiana M. Prowell; Mary W. Redman; Naiyer A. Rizvi; Rafael Rosell; Valerie Rusch; Dirk de Ruysscher; Lawrence H. Schwartz; Rajeshwari Sridhara; Rolf A. Stahel; Stephen Swisher; Janis M. Taube; William D. Travis; Patricia Keegan; Jacinta R. Wiens; Ignacio I. Wistuba; Murry W. Wynes; Fred R. Hirsch; Mark G. Kris

doi:10.1016/j.jtho.2018.09.017

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Gideon M. Blumenthal^*, Paul A. Bunn, Jamie E. Chaft, Caroline E. McCoach, Edith A. Perez, Giorgio V. Scagliotti, David P. Carbone, Hugo J. W. L. Aerts, Dara L. Aisner, Jonas Bergh, Donald A. Berry, Anthony Jarkowski, Nicholas Botwood, Darren A. E. Cross, Max Diehn, Nicole L. Drezner, Robert C. Doebele, Collin M. Blakely, Wilfried E. E. Eberhardt, Enriqueta FelipLuca Gianni, Steven P. Keller, Patrick J. Leavey, Shakun Malik, Francesco Pignatti, Tatiana M. Prowell, Mary W. Redman, Naiyer A. Rizvi, Rafael Rosell, Valerie Rusch, Dirk de Ruysscher, Lawrence H. Schwartz, Rajeshwari Sridhara, Rolf A. Stahel, Stephen Swisher, Janis M. Taube, William D. Travis, Patricia Keegan, Jacinta R. Wiens, Ignacio I. Wistuba, Murry W. Wynes, Fred R. Hirsch, Mark G. Kris

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.

Original language	English
Pages (from-to)	1818-1831
Number of pages	14
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	12
DOIs	https://doi.org/10.1016/j.jtho.2018.09.017
Publication status	Published - Dec 2018

Keywords

Neoadjuvant therapy
Induction chemotherapy
Resectable lung cancer
Pathologic response
Preoperative therapy
PATHOLOGICAL COMPLETE RESPONSE
POSITRON-EMISSION-TOMOGRAPHY
CHEMOTHERAPY PLUS SURGERY
CIRCULATING TUMOR-CELLS
1ST FDA APPROVAL
PHASE-II TRIAL
PREOPERATIVE CHEMOTHERAPY
RANDOMIZED-TRIAL
INTERNATIONAL ASSOCIATION
ADJUVANT CHEMOTHERAPY

Access to Document

10.1016/j.jtho.2018.09.017Licence: Free access - publisher

Cite this

Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J., Berry, D. A., Jarkowski, A., Botwood, N., Cross, D. A. E., Diehn, M., Drezner, N. L., Doebele, R. C., Blakely, C. M., Eberhardt, W. E. E., ... Kris, M. G. (2018). Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 13(12), 1818-1831. https://doi.org/10.1016/j.jtho.2018.09.017

@article{0f13fbee2685468dae36daeff1ba853a,

title = "Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer",

abstract = "This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.",

keywords = "Neoadjuvant therapy, Induction chemotherapy, Resectable lung cancer, Pathologic response, Preoperative therapy, PATHOLOGICAL COMPLETE RESPONSE, POSITRON-EMISSION-TOMOGRAPHY, CHEMOTHERAPY PLUS SURGERY, CIRCULATING TUMOR-CELLS, 1ST FDA APPROVAL, PHASE-II TRIAL, PREOPERATIVE CHEMOTHERAPY, RANDOMIZED-TRIAL, INTERNATIONAL ASSOCIATION, ADJUVANT CHEMOTHERAPY",

author = "Blumenthal, {Gideon M.} and Bunn, {Paul A.} and Chaft, {Jamie E.} and McCoach, {Caroline E.} and Perez, {Edith A.} and Scagliotti, {Giorgio V.} and Carbone, {David P.} and Aerts, {Hugo J. W. L.} and Aisner, {Dara L.} and Jonas Bergh and Berry, {Donald A.} and Anthony Jarkowski and Nicholas Botwood and Cross, {Darren A. E.} and Max Diehn and Drezner, {Nicole L.} and Doebele, {Robert C.} and Blakely, {Collin M.} and Eberhardt, {Wilfried E. E.} and Enriqueta Felip and Luca Gianni and Keller, {Steven P.} and Leavey, {Patrick J.} and Shakun Malik and Francesco Pignatti and Prowell, {Tatiana M.} and Redman, {Mary W.} and Rizvi, {Naiyer A.} and Rafael Rosell and Valerie Rusch and {de Ruysscher}, Dirk and Schwartz, {Lawrence H.} and Rajeshwari Sridhara and Stahel, {Rolf A.} and Stephen Swisher and Taube, {Janis M.} and Travis, {William D.} and Patricia Keegan and Wiens, {Jacinta R.} and Wistuba, {Ignacio I.} and Wynes, {Murry W.} and Hirsch, {Fred R.} and Kris, {Mark G.}",

year = "2018",

month = dec,

doi = "10.1016/j.jtho.2018.09.017",

language = "English",

volume = "13",

pages = "1818--1831",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Science",

number = "12",

}

Blumenthal, GM, Bunn, PA, Chaft, JE, McCoach, CE, Perez, EA, Scagliotti, GV, Carbone, DP, Aerts, HJWL, Aisner, DL, Bergh, J, Berry, DA, Jarkowski, A, Botwood, N, Cross, DAE, Diehn, M, Drezner, NL, Doebele, RC, Blakely, CM, Eberhardt, WEE, Felip, E, Gianni, L, Keller, SP, Leavey, PJ, Malik, S, Pignatti, F, Prowell, TM, Redman, MW, Rizvi, NA, Rosell, R, Rusch, V, de Ruysscher, D, Schwartz, LH, Sridhara, R, Stahel, RA, Swisher, S, Taube, JM, Travis, WD, Keegan, P, Wiens, JR, Wistuba, II, Wynes, MW, Hirsch, FR & Kris, MG 2018, 'Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer', Journal of Thoracic Oncology, vol. 13, no. 12, pp. 1818-1831. https://doi.org/10.1016/j.jtho.2018.09.017

TY - JOUR

T1 - Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

AU - Blumenthal, Gideon M.

AU - Bunn, Paul A.

AU - Chaft, Jamie E.

AU - McCoach, Caroline E.

AU - Perez, Edith A.

AU - Scagliotti, Giorgio V.

AU - Carbone, David P.

AU - Aerts, Hugo J. W. L.

AU - Aisner, Dara L.

AU - Bergh, Jonas

AU - Berry, Donald A.

AU - Jarkowski, Anthony

AU - Botwood, Nicholas

AU - Cross, Darren A. E.

AU - Diehn, Max

AU - Drezner, Nicole L.

AU - Doebele, Robert C.

AU - Blakely, Collin M.

AU - Eberhardt, Wilfried E. E.

AU - Felip, Enriqueta

AU - Gianni, Luca

AU - Keller, Steven P.

AU - Leavey, Patrick J.

AU - Malik, Shakun

AU - Pignatti, Francesco

AU - Prowell, Tatiana M.

AU - Redman, Mary W.

AU - Rizvi, Naiyer A.

AU - Rosell, Rafael

AU - Rusch, Valerie

AU - de Ruysscher, Dirk

AU - Schwartz, Lawrence H.

AU - Sridhara, Rajeshwari

AU - Stahel, Rolf A.

AU - Swisher, Stephen

AU - Taube, Janis M.

AU - Travis, William D.

AU - Keegan, Patricia

AU - Wiens, Jacinta R.

AU - Wistuba, Ignacio I.

AU - Wynes, Murry W.

AU - Hirsch, Fred R.

AU - Kris, Mark G.

PY - 2018/12

Y1 - 2018/12

N2 - This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.

AB - This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.

KW - Neoadjuvant therapy

KW - Induction chemotherapy

KW - Resectable lung cancer

KW - Pathologic response

KW - Preoperative therapy

KW - PATHOLOGICAL COMPLETE RESPONSE

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - CHEMOTHERAPY PLUS SURGERY

KW - CIRCULATING TUMOR-CELLS

KW - 1ST FDA APPROVAL

KW - PHASE-II TRIAL

KW - PREOPERATIVE CHEMOTHERAPY

KW - RANDOMIZED-TRIAL

KW - INTERNATIONAL ASSOCIATION

KW - ADJUVANT CHEMOTHERAPY

U2 - 10.1016/j.jtho.2018.09.017

DO - 10.1016/j.jtho.2018.09.017

M3 - (Systematic) Review article

SN - 1556-0864

VL - 13

SP - 1818

EP - 1831

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 12

ER -